Prospector
Profile
3-26-005
|
| |
| Ista Pharmaceuticals, Inc. |
NAICS |
325412 |
| 15295 Alton Parkway
Irvine, CA 92618 |
Description |
Ophthalmic Pharmaceuticals |
| (949) 788-6000 |
Employees |
222 |
| http://www.istavision.com/ |
Revenue |
(mil) |
58.8700 |
| |
Income |
(mil) |
-38.2200 |
| |
Assets |
(mil) |
71.7200 |
| |
Liability |
(mil) |
73.0200 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Ista Pharmaceuticals, Inc., reported a net loss of $38.22 million for the year ended December 31, 2007, slightly lower than the net losses of $38.42 million and $38.48 million reported during the years ended December 31, 2006 and 2005, respectively. The Company reported revenues of $58.87 million for the year ended December 31, 2007, as compared with net revenues of $33.0 million in 2006 and $10.66 million in 2005. As a result of its recurring losses, the Company's balance sheet at December 31, 2007, showed an accumulated deficit of $303.18 million.
|
| |
|
Intellectual Property:
The Company's success will depend on its ability to obtain patent protection for inventions, to preserve trade secrets and to operate without infringing the proprietary rights of third parties. It currently owns or licenses 23 United States and foreign pending patent applications and 61 United States and foreign issued patents. The Company seeks protection trade secrets and proprietary know-how, in part, through confidentiality and proprietary information agreements. The Company also files trademark applications to protect the names of products. [SEC Filing 10-K 03-07-08]
|
| |
|
Description:
Ista Pharmaceuticals, Inc., engages in the development and commercialization of ophthalmic products for serious eye diseases and conditions.
|
| |
|
Officers:
Richard C. Williams (Chair); Vicente Anido, Jr. (Pres., CEO, & Dir.); Lauren P. Silvernail (VP & CFO); Peter Barton Hutt (Dir.); Kathleen D. LaPorte (Dir.); Benjamin F. McGraw III (Dir.); Dean J. Mitchell (Dir.); Andrew J. Perlman (Dir.); Wayne I. Roe (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock Symbol ISTA; NasdaqGM;
32,923,116 common shares outstanding as of January 31, 2008.
|
| |
| |
| |
| return to main page |
